Investigational drug · Phase 3
Envudeucitinib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis, SLE.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
6
Any phase or sponsor naming "Envudeucitinib"
First trial start
2023
Jan 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Envudeucitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
- SLE
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Envudeucitinib" as an intervention, largest first.
- Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
Alumis IncIndustry
NCT06846541 · 1,680 participants (planned) · Start Jan 8, 2025 · Primary completion Nov 2028
Drug: Open-Label Envudeucitinib; Blinded Envudeucitinib and 1 more · For: Plaque Psoriasis; Psoriasis (PsO); Psoriasis and 2 more
Sites: Birmingham, Alabama; Chandler, Arizona; Pheonix, Arizona · 268 sites in all
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Alumis IncIndustry
NCT06586112 · 912 participants · Start Jul 25, 2024 · Primary completion Sep 19, 2025
Drug: Envudeucitinib; Apremilast and 1 more · For: Plaque Psoriasis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Rogers, Arkansas · 156 sites in all
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001Pivotal-lookingCompleted
Alumis IncIndustry
NCT06588738 · 862 participants · Start Aug 20, 2024 · Primary completion Sep 23, 2025
Drug: Envudeucitinib; Placebo and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 124 sites in all
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
Alumis IncIndustry
NCT05966480 · 408 participants · Start Jun 26, 2023 · Primary completion Jun 23, 2026
Drug: Envudeucitinib; Placebo · For: SLE
Sites: Anniston, Alabama; La Jolla, California; Los Alamitos, California · 169 sites in all
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisPivotal-lookingActive, not recruiting
Alumis IncIndustry
NCT05739435 · 165 participants · Start Jan 17, 2023 · Primary completion Dec 1, 2027
Drug: envudeucitinib · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Rogers, Arkansas · 38 sites in all
Alumis IncIndustry
NCT06952634 · 32 participants · Start Apr 29, 2025 · Primary completion Mar 24, 2026
Drug: envudeucitinib · For: Hepatic Impairment
Sites: Lake Forest, California; Miami Lakes, Florida; Orlando, Florida · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective Tyrosine Kinase 2 Targeting for the Management of Immune-mediated Inflammatory Skin Diseases: A New Paradigm.
De Luca DA, Koumprentziotis IA, Thaçi D · Am J Clin Dermatol 2026
- Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.
Hagino T, Kanda N · J Dermatol 2026
- The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
Burshtein J, Schlesinger T · J Clin Aesthet Dermatol 2026
- Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.
Armstrong AW, Krueger JG, Strober BE, et al. · Dermatol Ther (Heidelb) 2026
- From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.
Andrzejczak K, Sternak A, Witkowski W, et al. · Pharmaceutics 2026
- Response to Papp et al, "Efficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study".
Noot CH, Hopkins ZH, Feldman SR · J Am Acad Dermatol 2026
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- NetakimabPhase 32 trials
Biocad · Plaque Psoriasis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.